$32.82
2.85% today
Nasdaq, Nov 04, 09:18 pm CET
ISIN
US8753722037
Symbol
TNDM

Tandem Diabetes Care, Inc. Target price 2024 - Analyst rating & recommendation

Tandem Diabetes Care, Inc. Classifications & Recommendation:

Buy
68%
Hold
27%
Sell
5%

Tandem Diabetes Care, Inc. Price Target

Target Price $54.32
Price $31.91
Potential
Number of Estimates 19
19 Analysts have issued a price target Tandem Diabetes Care, Inc. 2025 . The average Tandem Diabetes Care, Inc. target price is $54.32. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 22 analysts: 15 Analysts recommend Tandem Diabetes Care, Inc. to buy, 6 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Tandem Diabetes Care, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Tandem Diabetes Care, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 747.72 891.07
6.68% 19.17%
EBITDA Margin -18.56% 0.23%
213.18% 101.24%
Net Margin -30.02% -12.60%
150.03% 58.03%

20 Analysts have issued a sales forecast Tandem Diabetes Care, Inc. 2024 . The average Tandem Diabetes Care, Inc. sales estimate is

$891m
Unlock
. This is
11.94% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$917m 15.19%
Unlock
, the lowest is
$885m 11.21%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $748m 6.68%
2024
$891m 19.17%
Unlock
2025
$995m 11.62%
Unlock
2026
$1.1b 11.64%
Unlock
2027
$1.3b 13.06%
Unlock
2028
$1.3b 5.26%
Unlock

16 Analysts have issued an Tandem Diabetes Care, Inc. EBITDA forecast 2024. The average Tandem Diabetes Care, Inc. EBITDA estimate is

$2.0m
Unlock
. This is
101.66% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$6.0m 104.85%
Unlock
, the lowest is
$-226k 99.82%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-139m 192.27%
2024
$2.0m 101.47%
Unlock
2025
$39.8m 1,856.09%
Unlock
2026
$78.9m 98.10%
Unlock
2027
$142m 80.47%
Unlock
2028
$169m 18.60%
Unlock

EBITDA Margin

2023 -18.56% 213.18%
2024
0.23% 101.24%
Unlock
2025
4.01% 1,643.48%
Unlock
2026
7.11% 77.31%
Unlock
2027
11.35% 59.63%
Unlock
2028
12.78% 12.60%
Unlock

21 Tandem Diabetes Care, Inc. Analysts have issued a net profit forecast 2024. The average Tandem Diabetes Care, Inc. net profit estimate is

$-112m
Unlock
. This is
17.91% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-90.3m 33.97%
Unlock
, the lowest is
$-128m 6.22%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-224m 133.33%
2024
$-112m 49.98%
Unlock
2025
$-77.5m 30.97%
Unlock
2026
$-47.0m 39.35%
Unlock
2027
$-11.8m 75.00%
Unlock
2028
$-7.4m 36.85%
Unlock

Net Margin

2023 -30.02% 150.03%
2024
-12.60% 58.03%
Unlock
2025
-7.79% 38.17%
Unlock
2026
-4.23% 45.70%
Unlock
2027
-0.94% 77.78%
Unlock
2028
-0.56% 40.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.43 -1.72
133.33% 49.85%
P/E negative
EV/Sales 2.37

21 Analysts have issued a Tandem Diabetes Care, Inc. forecast for earnings per share. The average Tandem Diabetes Care, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.72
Unlock
. This is
17.70% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.38 33.97%
Unlock
, the lowest is
$-1.96 6.22%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.43 133.33%
2024
$-1.72 49.85%
Unlock
2025
$-1.18 31.40%
Unlock
2026
$-0.72 38.98%
Unlock
2027
$-0.18 75.00%
Unlock
2028
$-0.11 38.89%
Unlock

P/E ratio

Current -15.25 194.97%
2024
-18.60 21.97%
Unlock
2025
-26.95 44.89%
Unlock
2026
-44.43 64.86%
Unlock
2027
-177.68 299.91%
Unlock
2028
-281.56 58.46%
Unlock

Based on analysts' sales estimates for 2024, the Tandem Diabetes Care, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.66 94.16%
2024
2.37 10.82%
Unlock
2025
2.13 10.41%
Unlock
2026
1.90 10.43%
Unlock
2027
1.68 11.55%
Unlock
2028
1.60 5.00%
Unlock

P/S ratio

Current 2.62 77.17%
2024
2.34 10.67%
Unlock
2025
2.10 10.41%
Unlock
2026
1.88 10.43%
Unlock
2027
1.66 11.55%
Unlock
2028
1.58 4.99%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today